Which neuroprotective agents are ready for bench to bedside translation in the newborn infant?
Institute of Women's Health, University College London, London, UK. n.robertson@ucl.ac.uk
Nicola J
NJ
Robertson
Sidhartha
S
Tan
Floris
F
Groenendaal
Frank
F
van Bel
Sandra E
SE
Juul
Laura
L
Bennet
Matthew
M
Derrick
Stephen A
SA
Back
Raul Chavez
RC
Valdez
Frances
F
Northington
Alistair Jan
AJ
Gunn
Carina
C
Mallard
D000493:Allopurinol / Q000627:therapeutic use; D001708:Biopterins / Q000031:analogs & derivatives / Q000627:therapeutic use; D004921:Erythropoietin / Q000627:therapeutic use; D006801:Humans; D007231:Infant, Newborn; D008550:Melatonin / Q000627:therapeutic use; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D052248:Nitric Oxide Synthase Type I / Q000037:antagonists & inhibitors; D057170:Translational Research, Biomedical; D014978:Xenon / Q000627:therapeutic use
D018696:Neuroprotective Agents; D004921:Erythropoietin; D001708:Biopterins; D014978:Xenon; D000493:Allopurinol; D052248:Nitric Oxide Synthase Type I; C003402:sapropterin; D008550:Melatonin